This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

KaloBios' KB001 Anti-Pseudomonas Antibody Study Published In Pediatric Pulmonology

Stocks in this article: KBIO

SOUTH SAN FRANCISCO, Calif., Sept. 18, 2013 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq:KBIO) today announced the publication of Phase 1 study results for KB001, a first generation, anti- Pseudomonas aeruginosa ( Pa) type III secretion system (TTSS) antibody, for use in patients with cystic fibrosis (CF). Data from this initial single dose clinical study supports the continuation of KaloBios' ongoing Phase 2 study of KB001-A, a second generation, anti-TTSS antibody in CF patients with chronic Pa infections. 

(Logo: http://photos.prnewswire.com/prnh/20130225/MM66380LOGO)

The Phase 1 study results appear online in the journal Pediatric Pulmonology, authored by Carlos Milla, M.D., of the Center for Excellence in Pulmonary Biology, Stanford University, and other members of the KB001 Study Group. 

"Many patients with CF are chronically infected with Pa which contributes to disease progression by causing a strong inflammatory response that destroys lung tissue," said Nestor A. Molfino, M.D., M.Sc, KaloBios Chief Medical Officer. "Treating Pa infection with antibiotics has long been shown to benefit CF patients; however, Pa is not eradicated by such treatments and antibiotic-resistant strains soon emerge. KB001-A is a novel, non-antibiotic agent against Pa that targets and inhibits the bacterium's TTSS that is responsible for Pa's virulence and pro-inflammatory effects.

"The safety, pharmacokinetic and pharmacodynamic results obtained for KB001 in this initial single-dose Phase 1 clinical study supports the continuation of the Phase 2 study currently underway of KB001-A as a potential non-antibiotic treatment to reduce airway inflammation and tissue damage in CF patients with chronic Pa infection," Dr. Molfino concluded.

The published study results showed a single intravenous dose of KB001 to have an acceptable safety profile and a trend toward a short-term reduction in markers of inflammation, particularly neutrophil elastase which has long been recognized as the main enzyme responsible for lung damage in CF patients. The investigators concluded that repeat-dosing studies are required to evaluate the durability of the anti-inflammatory effects and how treatment with KB001 might translate into clinical benefit.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,433.61 +46.40 0.27%
S&P 500 2,029.55 -27.54 -1.34%
NASDAQ 4,681.4970 -90.2660 -1.89%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs